IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Amgen reported interim Phase 3 results for tarlatamab with durvalumab as first-line maintenance treatment for extensive-stage small-cell lung cancer.
TL;DR
- Amgen said the combination reduced death risk by 58% versus the comparator in the DeLLphi-305 Phase 3 trial.
- The company reported a hazard ratio of 0.42 and median follow-up of approximately 16 months.
- The release describes interim trial results; longer follow-up and regulatory review remain pending.
Amgen said on October 24 that IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca’s IMFINZI (durvalumab) reduced death risk by 58% in the DeLLphi-305 Phase 3 trial. The study examined first-line maintenance treatment for extensive-stage small-cell lung cancer. [1] [2]
The company reported a hazard ratio of 0.42, a 95% confidence interval of 0.32 to 0.54 and a P value below 0.001. Median follow-up was approximately 16 months. [1]
Investing.com’s ESMO report described the results as strengthening the case for earlier use, while STAT also identified the data as a closely watched congress presentation. [2] [3]
These are interim sponsor-reported findings. The cited coverage does not establish long-term survival, a regulatory decision or how the combination compares with every current treatment option. [1] [2] [3]
Why it matters
The result could affect evaluation of the therapy earlier in the care pathway if sustained. For now, it is an interim trial finding rather than a regulatory decision.
Editor's note
The 58% figure and hazard ratio come from Amgen; secondary coverage is from Investing.com and STAT. No treatment advice.